We are live on ! Find out more

SPHS

Sophiris Bio, Inc.

SPHS

Delisted

SPHS was delisted on the 11th of March, 2020.

24 hedge funds and large institutions have $27.4M invested in Sophiris Bio, Inc. in 2014 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New

Increased

Maintained

Reduced

Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

9% more funds holding

Funds holding: 22 → 24 (+2)

17% less capital invested

Capital invested by funds: $33.1M → $27.4M (-$5.7M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders

Holders Change

Holders Change %

+9.09%

% of All Funds

0.69%

Holding in Top 10

–

Holding in Top 10 Change

-1

Holding in Top 10 Change %

-100%

% of All Funds

–

New

Increased

Reduced

Closed

Calls

–

Puts

–

Net Calls

–

Net Calls Change

–

Top Buyers

Rank	Fund	Capital Flow
1	GPP Great Point Partners Greenwich, Connecticut	+$471K
2	SC Sophrosyne Capital New York	+$368K
3	Bank of New York Mellon New York	+$49K
4	TRCT Tower Research Capital (TRC) New York	+$7.32K
5	Citigroup New York	+$1.88K

Top Sellers

Rank	Fund	Capital Flow
1	TCM Tang Capital Management San Diego, California	-$1.85M
2	First Manhattan New York	-$974K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
1	1 T. Rowe Price Associates Baltimore, Maryland	$5.38M	–	–	–
2	GPP 2 Great Point Partners Greenwich, Connecticut	$5M	+$471K	+120,340	+9%
3	3 Fidelity Investments Boston, Massachusetts	$4.77M	–	–	–
4	AG 4 Artal Group Luxembourg	$3.33M	–	–	–
5	5 First Manhattan New York	$2.5M	-$974K	-248,658	-25%
6	BI 6 BVF Inc San Francisco, California	$2M	–	–	–
7	7 Franklin Resources San Mateo, California	$1.67M	–	–	–
8	PAI 8 Palo Alto Investors Palo Alto, California	$975K	–	–	–
9	9 First Eagle Investment Management New York	$833K	–	–	–
10	SC 10 Sophrosyne Capital New York	$314K	+$368K	+93,900	New
11	11 Deutsche Bank Frankfurt Am Main Ge, Germany	$245K	–	–	–
12	12 TD Asset Management Toronto, Ontario, Canada	$196K	–	–	–
13	13 Stifel Financial St. Louis, Missouri	$49K	+$58.1K	+14,825	New
14	14 Bank of New York Mellon New York	$42K	+$49K	+12,500	New
15	BIM 15 Baldwin Investment Management West Conshohocken, Pennsylvania	$35K	–	–	–
16	V 16 Veritable Wilmington, Delaware	$35K	–	–	–
17	TRCT 17 Tower Research Capital (TRC) New York	$7K	+$7.32K	+1,868	+1,868%
18	18 Bank of Montreal Toronto, Ontario, Canada	$6K	–	–	–
19	19 Royal Bank of Canada Toronto, Ontario, Canada	$2K	+$376	+96	+15%
20	20 Citigroup New York	$2K	+$1.88K	+479	+439%
21	21 AllianceBernstein Nashville, Tennessee	$1K	–	–	–
22	22 Morgan Stanley New York	$1K	+$106	+27	+14%
23	U 23 UBS Zurich, Switzerland	$1K	+$1K	+256	+457%
24	TCM 24 Tang Capital Management San Diego, California	–	-$1.85M	-500,000	Closed

SPHS Hedge Fund Activity: Q1 2014 in Review

24 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q1 2014, worth a combined $27.4M — down 17% from $33.1M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SPHS positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Great Point Partners, adding an estimated $471K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.85M sold.

24 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q1 2014, up from 22 in Q4 2013.
Funds reported $27.4M of Sophiris Bio, Inc. stock for Q1 2014, down 17% quarter-over-quarter.
3 funds opened new Sophiris Bio, Inc. positions in Q1 2014 and 1 closed out, a net change of +2 holders.
The largest Sophiris Bio, Inc. buyer in Q1 2014 was Great Point Partners, an estimated $471K added.
The largest Sophiris Bio, Inc. seller in Q1 2014 was Tang Capital Management, an estimated $1.85M sold.

Based on aggregated 13F filings for Q1 2014.

Sophiris Bio, Inc. SPHS